關(guān)鍵詞

司柏索利單抗?三聯(lián)療法 耐藥性檢測?CRISPR-Cas12a 莫格利珠單抗?胰島素樣生長因子1受體 阿爾茨海默病?替雷利珠單抗 罕見病

?

#今日行業(yè)熱點(diǎn)#

①The Lancet：Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

臨床試驗：司柏索利單抗（Spesolimab）用于預(yù)防廣泛性膿皰性銀屑病(Effisayil 2)的有效性和安全性:一項國際、多中心、隨機(jī)、安慰劑對照試驗

DOI: 10.1016/S0140-6736(23)01378-8

②The Lancet Gastroenterology and Hepatology：Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

三聯(lián)療法與圍手術(shù)期化療用于局部晚期食管和食管胃結(jié)合部腺癌(Neo-AEGIS):一項開放標(biāo)簽、隨機(jī)、Ⅲ期試驗

DOI: 10.1016/S2468-1253(23)00243-1

③The Lancet Microbe：Xpert MTB/RIF Ultra on contaminated liquid cultures for tuberculosis and rifampicin-resistance detection: a diagnostic accuracy evaluation

使用Xpert MTB / RIF Ultra（Ultra）方法對污染液體培養(yǎng)物進(jìn)行結(jié)核和利福平耐藥性檢測的診斷準(zhǔn)確性評價

DOI: 10.1016/S2666-5247(23)00169-6

④The Lancet Microbe：Rapid detection of monkeypox virus using a CRISPR-Cas12a mediated assay: a laboratory validation and evaluation study

利用CRISPR-Cas12a介導(dǎo)的試驗快速檢測猴痘病毒:一項實(shí)驗室驗證和評估研究

DOI: 10.1016/S2666-5247(23)00148-9

⑤The Lancet Microbe：Mogamulizumab for Treatment of Human T-lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Single-Center US-based Series

莫格利珠單抗（Mogamulizumab）用于人類嗜T淋巴細(xì)胞病毒1型（HTLV-1）相關(guān)脊髓病/熱帶痙攣性癱瘓:美國單中心系列研究

DOI: 10.1093/cid/ciad281

⑥Journal of the American Heart Association：Insulin‐Like Growth Factor 1 Receptor Deficiency Alleviates Angiotensin II–Induced Cardiac Fibrosis Through the Protein Kinase B/Extracellular Signal‐Regulated Kinase/Nuclear Factor‐κB Pathway

胰島素樣生長因子1受體(IGF-1R)缺乏通過蛋白激酶B（Akt）/細(xì)胞外信號調(diào)節(jié)激酶（ERK）/核因子κB（NF-kB）途徑減輕血管緊張素Ⅱ（Angiotensin II）誘導(dǎo)的心臟纖維化

DOI: 10.1161/JAHA.123.029631

⑦乙酰膽堿酯酶抑制劑琥珀八氫氨吖啶片用于輕、中度阿爾茨海默病的III期臨床試驗已完成揭盲和主要數(shù)據(jù)的統(tǒng)計分析，達(dá)到主要終點(diǎn)

⑧靶向VEGFR2的TKI創(chuàng)新藥阿帕替尼用于復(fù)發(fā)或轉(zhuǎn)移性腺樣囊性癌的國際Ⅱ期臨床結(jié)果積極

⑨替雷利珠單抗單藥用于既往接受過含鉑化療的不可切除、局部晚期或轉(zhuǎn)移性食管鱗狀細(xì)胞癌（ESCC）的適應(yīng)癥已獲歐盟委員會（EC）批準(zhǔn)

⑩國家衛(wèi)健委等六部門聯(lián)合發(fā)布《第二批罕見病目錄》共納入86種罕見疾病，目前，我國共有207種罕見病

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！